Moderna to expand child vaccine trial to get more safety data
The Peninsula
Moderna Inc. said it would expand an ongoing trial of its coronavirus vaccine in kids under 12 years old to gather more safety data, amid worries that messenger RNA shots may trigger rare heart side effects.
"The objective is to enroll a larger safety database which increases the likelihood of detecting rarer events,” a Moderna spokeswoman said in a statement. Trial timelines are regularly re-evaluated based on regulatory agency discussions and requests, she said, but Moderna currently expects to have data that would support authorization in late 2021 or early 2022.More Related News